Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business IPO

ADARx Pharmaceuticals $1.74B US IPO

Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026

Sentiment
15
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The listing signals continued investor appetite for later-stage biotech assets and provides a valuation benchmark for the RNA therapeutics space, potentially encouraging further biotech IPO filings. AbbVie's anchor investment offers external validation of ADARx's platform, though elevated Treasury yields and interest rates keep the broader IPO window selective and could pressure pricing.

biotechnology pharmaceuticals investment banking

ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its US initial public offering. The company aims to raise up to $371.9 million by offering 21.9 million shares priced between $15 and $17 each, and plans to list on Nasdaq under the symbol ADRX. AbbVie has agreed to invest up to $100 million in a concurrent private placement that would give it a roughly 4.9% stake in ADARx following the IPO; AbbVie had previously paid ADARx $335 million in May 2025 for a research collaboration. The offering is underwritten by JPMorgan, Morgan Stanley, Toronto-Dominion Bank — TD Cowen, UBS Investment Bank and LifeSci Capital. The IPO comes amid a selective reopening of the biotech listing market, with peers Retension Pharmaceuticals and TRex Bio filing for listings and Bicara Therapeutics debuting after raising $350 million in an upsized IPO, even as elevated Treasury yields and higher interest rates have pushed some prospective issuers to the sidelines. ADARx's most advanced candidate, onvuzosiran, is in late-stage testing for hereditary angioedema, with three programs in clinical testing and two in advanced preclinical development.

95 ADARx Pharmaceuticals sought IPO valuation
80 AbbVie agreed to invest ADARx Pharmaceuticals
60 ADARx Pharmaceuticals planned Nasdaq listing Nasdaq
30 Bicara Therapeutics debuted after raising
25 TRex Bio filed for listing
25 Retension Pharmaceuticals filed for listing
priv
The central entity of the event, seeking up to $1.74 billion valuation and $371.9 million in proceeds via a Nasdaq listing under ADRX. A successful IPO would fund late-stage trials of onvuzosiran and validate its RNA drug platform.
Importance 100.0 Sentiment 30.0
stock
Agreed to invest up to $100 million in a concurrent private placement for a roughly 4.9% post-IPO stake, deepening an existing collaboration after a $335 million payment in May 2025. The move signals continued big-pharma appetite for external innovation.
Importance 70.0 Sentiment 10.0
exch
The exchange where ADARx plans to list under the symbol ADRX, adding another biotech listing to its roster.
Importance 30.0 Sentiment 5.0
stock
Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
stock
Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Importance 25.0 Sentiment 5.0
subs
Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Importance 20.0 Sentiment 5.0
stock
Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Importance 20.0 Sentiment 5.0
priv
Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Importance 15.0 Sentiment 5.0
priv
Cited as a peer that debuted after raising $350 million in an upsized IPO, illustrating the reopened biotech listing window.
Importance 15.0 Sentiment 10.0
cnt
The venue for the IPO, with elevated Treasury yields and higher interest rates shaping a selective backdrop for new listings.
Importance 10.0 Sentiment 0.0
priv
Cited as a peer that filed for a listing, part of the wave of biotech IPO activity.
Importance 10.0 Sentiment 5.0
priv
Cited as a peer that filed for a listing, part of the wave of biotech IPO activity.
Importance 10.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.